Product Description
Feasibility Studies, Analytical Development, Scale-up Capabilities, GMP Clinical Trial Material, GMP Contract Manufacturing
Since 1997, Oakwood Laboratories has been committed to developing global pharmaceutical products, using our Chroniject™ technology platform, that provide enhanced therapeutic benefits to patients worldwide throughout a variety of disease states. Oakwood is also dedicated to adhering to the highest quality standards for all projects, while maintaining successful alliances with strategic partners globally.
Oakwood is a specialty pharmaceutical company focused on the development and manufacture of sustained release injectable products using Chroniject™, our polymer microsphere-based drug delivery technology platform. We operate a fully equipped and staffed R&D facility, and an FDA approved aseptic cGMP manufacturing facility specifically designed to manufacture clinical and commercial material for our long-acting injectable products. Oakwood has worked on a wide array of partnered and internal programs. The most advanced programs utilizing the technology have progressed through Phase III global clinical trials. In addition to its CDMO microsphere development servcices, Oakwood uses its GMP manufacturing facility to perform contract manufacturing (CMO) of standard sterile injectables for external parties Oakwood currently manufactures five (5) commercial products.
Oakwood develops and manufactures sustained release injectable products using its Chroniject™ technology platform. This platform offers many benefits including flexible release durations from one week to one year, compatibility with a variety of different molecule types (small molecules, peptides, and proteins), and applications within multiple therapeutic indications (CNS, ophthalmology, oncology, osteoarthritis, and animal health). Oakwood has over 25+ years experience using our Chroniject™ technology. Over that time, we have developed expertise on which parameters to change to yield the desired product profile. We have also developed strategic global partnerships to assist with the development process such as polymer and raw material supply. These initiatives have propelled Oakwood as a top-ranking company within the long-acting injectable market.
Oakwood Labs was founded as a division of Ben Venue Laboratories, to develop sustained release injectable products. At that time, Ben Venue was the largest independent injectable pharmaceutical manufacturer in the United States. The founders of Oakwood, Edward C. Smith and Mark T. Smith, were senior executives at Ben Venue until its acquisition by Boehringer Ingleheim in 1997. Prior to the sale, Oakwood was spun off as an independent entity, and set up its headquarters and R&D facility in Oakwood Village, Ohio. In 2002, Oakwood built its manufacturing facility in nearby Solon, Ohio.
